IFNA17 and prostate carcinoma: Analysis of CHRM4-driven IFNA17 cytokine release in the prostate cancer TME following ADT resistance may provide a clear understanding of the feedback loop consisting of CHRM4/AKT/MYCN in the context of AR inhibition.